Effect of APACHE-II and the Age-Adjusted CHARLSON Comorbidity Index at Predicting Mortality in Patients with COVID-19

Yıl 2022, Cilt: 5 Sayı: 3, 430 - 437, 01.09.2022

Şermin Eminoglu , Seyda Efsun Ozgunay

https://doi.org/10.19127/bshealthscience.1109017

Öz

The COVID-19 pandemic disproportionately affects patients with comorbidities. Comprehensive comorbidity assessment is important in establishing the risk stratification of patients with COVID-19 after hospital admission. In this study, our aim is to investigate the effectiveness of Acute Physiology and Chronic Health Assessment II (APACHE-II) and Age Adjusted Charlson Comorbidity Index (ACCI) in predicting mortality in COVID-19 patients admitted to the Intensive Care Unit (ICU). Patients aged >18 years who were admitted to the intensive care unit with the diagnosis of COVID-19 pneumonia in the Health Sciences University Bursa Yüksek İhtisas Training and Training Hospital between July 2021 and September 2021 were included in the study. The medical records of the patients were then scanned into the hospital automation system. Demographics, comorbidities, clinical features, laboratory parameters, APACHE-II score, treatments, and outcomes were recorded in a standard form. ACCI score was calculated from the data and recorded. The 276 patients analyzed were divided into two groups as surviving (n=129) and developing mortality (n=147). The mortality rate was 58.93%, mostly male (58%), median age 65 years, ACCI score 1 (IQR.3) and APACHE-II score 2 (IQR.8). There was no difference between the groups in terms of age, gender distribution and APACHI-II score (P= 0.519, P= 0.927, P= 0.364, respectively). The groups did not differ in terms of comorbidity except for chronic renal failure (CRF), and CRF was significantly higher in patients who developed mortality (P= 0.037). The ACCI score was found to be higher in patients who developed mortality (P= 0.034). Death risk; Those with an ACCI score of >2 were 2.26 times higher than those with an ACCI score of ≤2 (P= 0.021). The APACHI-II score did not differ between the groups in terms of mortality (P= 0.380). As a result, high ACCI score was found to be effective in predicting mortality. It could potentially be used to identify at-risk patients infected with COVID-19 and to predict their clinical status.

Anahtar Kelimeler

COVID-19 pneumonia, Comorbidity, Index, APACHI-II score, Intensive care unit, Mortality

Kaynakça

• Abate SM, Ali SA, Mantfardo B, Basu B. 2020. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One, 15: e0235653.
• Bannay A, Chaignot C, Blotière PO. 2016. The best use of the Charlson comorbidity index with electronic health care database to predict mortality. Med Care, 54:188-194.
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis, 40: 373-383.
• Chen J, Liu B, Du H, Lin H, Chen C, Rao S, Yu R, Wang J, Xue Z, Zhang Y, Xie Y. 2021. Performance of CURB-65, PSI, and APACHE-II for predicting COVID-19 pneumonia severity and mortality. Eur J Inflamm, 19: 1-12.
• Cheng P, Wu H, Yang J, Song X, Xu M, Li B, Zhang J, Qin M, Zhou C, Zhou X. 2021. Pneumonia scoring systems for severe COVID-19: which one is better. Virol J, 18: 1-9.
• Christensen DM, Strange JE, Gislason G, Torp-Pedersen C, Gerds T, Fosbøl E, Phelps M. 2020.Charlson comorbidity index score and risk of severe outcome and death in Danish COVID-19 patients. J Gen Intern Med, 35: 2801-2803
• Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, Li Y, Cheng L, Li W, Jia H, Ma X. 2020. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging, 12: 12493-12503.
• Ferroni E, Giorgi Rossi P, Spila Alegiani S. 2020. Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID-19 network. Clin Epidemiol, 12: 1337-1346.
• Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, Liu X, Chen R, Tang C, Wang T, Ou C, Li L, Chen P, Sang L, Wang W, Li J, Li C, Ou L, Cheng B, Xiong S, Ni Z Xiang J, Hu Y, Liu L, Shan H, Lei C, Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J, Ye C, Zhu S, Cheng L, Ye F, Li S Zheng J, Zhang N, Zhong N, He J. 2020. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J, 55:2000547.
• Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, Vanood A, Ibironke O, Hanna A, Ranski A, Halalau A. 2020. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med, 288: 469-476.
• Kim DH, Park HC, Cho A, Kim J, Yun KS, Kim J, Lee YK. 2021. Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection. Medicine, 100: e25900.
• Kuswardhani RAT, Henrina J, Pranata R, Lim MA, Lawrensia S, Suastika K. 2020. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr, 14: 2103-2109.
• Li X, Xu S, Yu M, Wang k, Tao Y, Zhou y, Shi J, Zhou M, WU B, Yang Z, Zhang C, Yue J, Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. 2020. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol, 146: 110-118.
• Ministry of Health. 2021. COVID-19 Yeni koronavirüs hastaliği. URL: https:// covid19 bilgi.saglik.gov.tr (accessed date: April 25, 2022).
• Pérez FM, Pino JLD, García NJ, Ruiz EM, Méndez CA, Jiménez JMG, Romero FN, Rodriguez MVN. 2020. Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. Rev Clin Esp, 221: 529-535.
• Plotnikow GA, Matesa A, Nadur JM, Alonso M, Nuñez I, Vergara G, Alfageme MJ, Vitale A, Gil M, Kinzler V, Melia M, Pugliese F, Donnianni M, Pochettino J, Brozzi I, Scapellato JL. 2020. Characteristics and outcomes of patients infected with nCoV19 requiring invasive mechanical ventilation in Argentina. Rev Bras Ter Intensiva, 32: 348-353.
• Richards G, Levy H, Laterre PF, Feldman C, Woodward B, Bates BM, Qualy RL.2011. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med, 26: 34-40.
• Sabaz MS, Aşar S. 2021. Association of Charlson Comorbidity and Pneumonia Severity Indices with Mortality in Patients with Coronavirus Disease-2019 in the Intensive Care Unit. J Turk Soc Intens Care, 19: 33-41
• Shanbhag V, Arjun NR, Chaudhuri S, Pandey AK. 2021. Utility of Age-adjusted Charlson Comorbidity Index as a Predictor of Need for Invasive Mechanical Ventilation, Length of Hospital Stay, and Survival in COVID-19 Patients. Indian J Crit Care Med, 35: 987-991.
• Sun D, Ding H, Zhao C, Li Y, Wang J, Yan j, Wang DW. 2017. Oncotarget, 8: 63073-63083.
• Varol Y, Hakoglu B, Cirak AK, Polat G, Komurcuoglu B, Akkol B, Atasoy C, Bayramic E, Balci G, Ataman S, Ermin S, Yalnız E. 2021. The impact of charlson comorbidity index on mortality from SARS‐CoV‐2 virus infection and A novel COVID‐19 mortality index: CoLACD. Int J Clin Pract, 75: e13858.
• WHO. 2022. COVID-19 dashboard. Geneva: World Health Organization. URL: https://covid19.who.int/ (accessed date: April 25, 2022).
• Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, pan S, Zou X, Yuan S, Shang Y. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 8: 475-481.
• Zhou Y, Fan, H. 2021. Clinical characteristics and outcomes among patients with Covid-19 in different regions of the world. J Coll Physicians Surg Pak, 30:11-15
• Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, Yu S, Jing L, Li D, Huang J. 2020. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med, 48: e657-e665.